We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Ninlaro

News List

Takeda Provides Update on TOURMALINE-MM2 Phase 3 Trial americanpharmaceuticalreview
March 11, 2020
Takeda Pharmaceutical announced the results from the TOURMALINE-MM2 study designed to evaluate the addition of NINLARO™ (ixazomib) to lenalidomide and dexamethasone in newly diagnosed transplant ineligible multiple myeloma patients.
Takeda hits FDA snag on Ninlaro, but its growth still helps drive revenue hike fiercepharma
February 24, 2019
In Takeda’s last quarterly report as a separate company from Shire, things seem to be going its way—key drugs are growing nicely, Shire integration is on track, and cash-raising sell-offs are underway, executives said.
Takeda's Ninlaro clears Phase 3 endpoint as maintenance therapy in multiple myeloma pharmafile
July 17, 2018
After making headlines with its mammoth deal to acquire Shire earlier this year, Takeda has emerged with new Phase 3 data for its oral proteasome inhibitor Ninlaro (ixazomib).